Page 100

Mayo 2016

artículos de revisión Ancho de distribución eritrocitaria y enfermedades cardiovasculares - H. Alcaíno et al 47. Burger D, Schock S, Thompson CS, Montezano AC, Hakim AM, Touyz RM. Microparticles: biomarkers and beyond. Clin Sci (Lond) 2013; 124 (7): 423-41. 48. Lannan KL, Phipps RP, White RJ. Thrombosis, platelets, 642   microparticles  and PAH: more than a clot. Drug Discov Today 2014; 19 (8): 1230-5. 49. Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T. Association of platelet-derived  microparticles  with C-C chemokines  on vascular complication in patients with acute myocardial infarction. Clin Appl Thromb Hemost 2002; 8 (3): 279-86. 50. Mesri M,  Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 161 (8): 4382-7. 51. Barry OP, Kazanietz MG, Praticò D, FitzGerald GA. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase dependent pathway. J Biol Chem 1999; 274 (11): 7545-56. 52. Biró E, Lok CA, Hack CE, van der Post JA, Schaap MC, Sturk A, et al. Cell-derived microparticles and complement  activation in preeclampsia versus normal pregnancy. Placenta 2007; 28 (8-9): 928-35. 53. Schock SC, Edrissi H, Burger D, Cadonic R, Hakim A, Thompson C. Microparticles generated during chronic cerebral ischemia deliver proapoptotic signals to cultured endothelial cells. Biochem Biophys Res Commun 2014; 450 (1): 912-7. 54. Rousseau M, Belleannee C, Duchez AC, Cloutier N, Levesque T, Jacques F, et al. Detection and quantification of  microparticles  from different cellular lineages using flow cytometry. Evaluation of the impact of secreted  phospholipase A2 on microparticle assessment. PLoS One 2015; 10 (1): e0116812. 55. Lippi G, Pavesi F, Bardi M, Pipitone S. Lack of harmonization of red blood cell distribution width (RDW). Evaluation of four hematological analyzers. Clin Biochem 2014;47 (12): 1100-3. 56. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predicts death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330 (7492): 625. 57. Troughton R, Michael Felker G, Januzzi JL Jr. Natriuretic peptide-guided heart failure management. Eur Heart J 2014; 35 (1): 16-24. 58. Baeza R, Corbalán R, Castro P, Acevedo M, Quiroga T, Viviani P. Coronary biomarkers and long-term clinical outcome in acute coronary syndrome without ST segment elevation. Rev Med Chile 2005: 133: 1275-93. 59. Turgutalp K, Kıykım A, Bardak S, Demir S, Karabulut Ü, Özcan T, et al. Is the red cell distribution width strong predictor for treatment response in primary glomerulonephritides? Ren Fail 2014; 36 (7): 1083-9. Rev Med Chile 2016; 144: 634-642


Mayo 2016
To see the actual publication please follow the link above